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Abstract
A growing body of scientific reports suggests a relevant key role of human intes-
tinal microbiota (HIM) in maintaining the host’s physiological and mental balance; 
thus any disturbance in the microbiota diversity and/or concentrations may result 
in impaired stimulation of the gastrointestinal (GI) system-central nervous system 
(CNS) bidirectional pathway, termed gut-to-brain axis. Recent data show that HIM 
composition is significantly unbalanced among a subset of autism spectrum dis-
order (ASD) subjects, as compared with non-ASD siblings or age-matched control 
subjects. Several authors claim that specific changes in HIM (diet-based alteration 
of Bacteroidetes/Firmicutes ratio and death of predominant microbiota after 
antibiotic treatments, among others) could either trigger or be highly associated 
events with persistent ASD signs and behaviors. Whether HIM plays a causative or 
a circumstantial role in ASD severity, then HIM manipulation might be applied as a 
therapeutic alternative to improve ASD clinical manifestations and behaviors.
Keywords: human intestinal microbiota, dysbiosis, gut-to-brain axis,  
autism spectrum disorders, short-chain fatty acids
1. Introduction
Communication between the gastrointestinal (GI) system and the central 
nervous system (CNS) occurs constantly and plays a critical role in maintain-
ing the healthy status. That communication engages a bidirectional stimulation 
system, involving not only the brain and gut cells but endocrine-, immune-, and 
microbiota-derived components as well, the so-called gut-to-brain axis (GBA) 
[1, 2]. Consequently, impaired communication between both ends of the GBA, 
associated with or as consequence of disturbance of the GI microbial diversity, has 
been associated with a negative health outcome later in life [1, 3].
Increasing evidence points out that there is a link between alterations of gut 
microbiota and several disorders of the central nervous system including autism 
spectrum disorders (ASD) depression, anxiety, irritable bowel syndrome, attention 
deficit and hyperactivity disorder (ADHD), Parkinson’s disease, disorders of mood 
and affect, and chronic pain [3–5].
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The abovementioned psychiatric disorders frequently co-occur with each other, 
but interestingly they also occur in comorbidity with metabolic disorders, such as 
diabetes, cardiovascular disease, and metabolic syndrome [6–8], and are associated 
with adverse outcomes including higher mortality [6]. The insights of how those 
disorders are linked remain unclear. One likely explanation is that gut microbiota 
can trigger and guide the communication network of GBA and subsequently alter 
metabolic and psychological equilibrium [3, 5, 7, 8].
ASD are a heterogeneous set of lifelong neurodevelopmental diseases, whose 
incidence increased significantly over the past decades [9]. No unique etiology 
of ASD has been identified, though both genetic and environmental factors have 
been suggested [9, 10]. However, findings of candidate genes do not conclusively 
explain the etiopathology of ASD; thus, scientific research has been redirected to GI 
comorbidities of ASD, under the premise that the high frequency of gut microbiota 
alterations seen in these patients may be associated with autism symptoms severity 
[10]. Indeed, the independent observations of Rodakis [10] and Sandler et al. [11] 
about improvements in autism clinical manifestations after antibiotic treatments 
prompted intense research around the issue, including therapeutic interventions 
such as diet modification, supplementation with biotics (prebiotics, probiotics, 
synbiotics, and/or postbiotics), alternative antibiotic treatments, and fecal micro-
biota transplantation, among others, with variable outcomes [12].
2. Human intestinal microbiota
Colonization of the human body occurs after birth, and possibly before birth, 
with a diverse microbial community of archaea, bacteria, fungi, viruses, and pro-
tozoa. This diverse community is referred to as the HIM. The prokaryote organisms 
colonizing the human body encompass nearly 90% of all HIM [13, 14]. Resident 
microbiota of the human GI tract, the one that colonizes permanently, is one of the 
most densely populated communities, even more so than the soil, the subsoil, and 
the oceans [15].
Colonization of GI tract is influenced by many factors like mode of birth 
delivery, infant feeding method, and the environment (stress, frequency of exer-
cise, hygiene habits, infections, pharmaceuticals use, and type of feeding) [16, 17]. 
Within the human intestinal microbiota, there are both types of microorganisms: 
those who are essential, and even indispensable, for the survival of the host, and 
those who are potentially pathogenic. The vast majority have beneficial rather than 
detrimental effects on the host’s health [15].
The importance of the GI microbiota was overlooked for a long time, and efforts 
to determine its composition and functions were unsuccessful; on the one hand, 
cultures from stool samples are unproductive, and on the other hand, according to 
estimations, 80% of the GI microbiota are anaerobe uncultivable organisms [10]. 
Anaerobic bacteria outnumber aerobic and facultative anaerobic bacteria by 100- to 
1000-fold [16, 17]. Calculations of microbial counts in the colon of adult humans 
reach a mean of 1011 organisms/gram of wet stool, a quantity updated that is similar 
to the total number of human cells [18]. Estimated HIM composition comprise up 
to 1800 genera representing 7000–40,000 bacterial strains belonging to 500–1000 
resident species [17, 18].
Taking into account the presence of gene content and metabolic products, along 
with the microbiota organisms contained within a particular body site, we must 
refer to it as a microbiome [15]. Studies on composition and function of uncultured 
microbial communities, more specifically by sequencing-based assays, are referred 
to as metagenomics. First, community DNA is extracted from a sample containing 
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multiple microbial members. Second, bacterial taxa present in the community are 
then defined by amplification of the 16S rRNA gene followed by sequencing. Highly 
similar sequences are grouped into operational taxonomic units (OTUs) or phylo-
types, which can be compared to 16S rRNA databases to identify them as accurately 
as possible. An alternate method identifies community taxa after the total DNA is 
metagenomically sequenced and compared to reference genomes or gene catalogs. 
The OTUs can be described in terms of their relative abundance and/or their 
phylogenetic relationships, while sequenced genomes can be described as relative 
abundances of its genes and pathways [19].
The human intestinal microbiome is mainly defined by the high abundance 
of two bacterial phylotypes: Bacteroidetes and Firmicutes. Other phylotypes 
present at lesser amounts are Proteobacteria, Actinomyces, Fusobacterium, and 
Verrucomicrobia [14]. The gut microbiome is conformed with nearly 470 phy-
lotypes, more than 1000 bacterial species representing more than 5000 strains, 
which in turn encode between 5 and 10 million of nonredundant genes (150-fold 
the number of genes identified in the human genome) [16, 17]. Studies on intestinal 
microbiome in health and disease revealed two microbiome subpopulations, one 
with high-gene counts and the other with low-gene counts; the first one seems to be 
associated with a healthy digestive status [20, 21].
Every person has a unique microbiome profile; still there is a reduced number of 
species shared between persons. The aforesaid feature allowed to classify individu-
als into one of three enterotypes, each one based on the proportions of the three 
predominant intestinal genera, based on their abundance, Bacteroides, Prevotella, 
and Ruminococcus. The first two genera represent the Bacteroidetes, and the last one 
represents the Firmicutes. Enterotype 1 shows predominance of Bacteroides, while 
enterotypes 2 and 3 were defined by predominance of Prevotella and Ruminococcus, 
respectively [22].
Alterations of the typical GI microbiota, in number and abundance distribution 
of distinctive types of microorganisms, and the host’s adverse response to such 
changes have been called as dysbiosis. Thus, dysbiosis with low diversity has been 
linked particularly with obesity, inflammatory bowel disease, and ASD [16].
There are two ongoing multi-group projects on human microbiome, the Europe-
based Metagenomics of the Human Intestinal Tract (MetaHIT) and the US-based 
Human Microbiome Project (HMP). Both of them will allow to define to its finest 
details the microbiome diversity, at least to species level, their genetic load, and how 
microbiota interacts with the host [23, 24].
2.1 Biological role of GI microbiota
The intestinal microbiota maintains a symbiotic relationship with the host. 
Studies in both humans and mammals have implicated the intestinal microbiome in 
several physiological processes that are pivotal to the host health, from food diges-
tion and energy homeostasis to immune and neurobehavioral development [25].
The single layer of intestinal epithelial cells, connected by tight junctions, 
constitutes itself a physical and biochemical barrier that segregates the commensal 
microbiota organisms to maintain intestinal homeostasis. This occurs through 
regulation of nutrients, electrolytes, and water absorption, as well as through 
release of mucins, antimicrobial peptides, and IgA for the prevention of the entry 
of pathogenic microorganisms [26–28]. The interaction between the microbiota and 
intestinal epithelial cells also promotes tissue restoration in the setting of injury or 
acute inflammation, thus supporting epithelium integrity. Besides the above state-
ment, the microbiota provides protection against exogenous pathogenic organisms, 
either through competition for common nutrients and niches or by prompting 
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development and functional maturation of the gut immune system, including 
gut-associated lymphoid tissue, T-helper 17 cells, inducible regulatory T cells, IgA-
producing B cells, and innate lymphoid cells [13].
The HIM microbiota has a considerable input on the metabolomic profile, the 
complete set of intestinal metabolites, of the host [29]. Specifically, the microbiota 
is a major source of both circulating organic acids and tryptophan metabolites, 
which have beneficial effects on the host health (Table 1) [30–53].
Fermentative processes of nondigestible complex carbohydrates, from dietary 
fiber, by Firmicutes and Bacteroidetes, result in the production of various short-
chain fatty acids (SCFAs), such as acetate, propionate, butyrate, isobutyrate, valer-
ate, and isovalerate. These bacteria-derived SCFAs, in a physiological context, may 
serve as an energy source for enterocytes, stimulate water and sodium absorption, 
decrease colonic pH, etc. [30].
Hyperproduction or deficiency of SCFAs may also affect the pathogenesis of 
a diverse range of diseases, from allergies and asthma to neurological diseases 
[17, 29, 30]. For example, a diet high in fat and digestible saccharides provokes that 
majority of nutrients be absorbed in the duodenum, leaving very few substrates 
for the colonic bacteria, leading to dysbiosis. Higher levels of SCFAs can also alter 
the intercellular spaces between the cells, resulting in a leaky gut that allows for 
more metabolites and bacteria to pass through the epithelial barrier, where bacterial 
endotoxins and other microbial-derived metabolites can gain entry into the blood-
stream [17] Furthermore, dysbiosis can affect host immunity and neurobehavioral 
responses [17, 29]. Among SCFAs, butyrate is a promoter of colonic functionality 
and physical integrity, via cholesterol-rich membrane microdomain, as well as the 
preferred metabolic substrate for the colonocytes’ energy requirements [54].
Essential vitamins such as folate, vitamin K, and vitamin B12, for the host’s 
growth, are synthesized by gut microbiota, which in turn may affect DNA and his-
tone protein methylation [55–57]. Certain hormones and vitamins also participate 
in drug and poison removal [58].
Apart from carbohydrates, GI bacteria also metabolize complex lipids and 
proteins that are indigestible by the host [59–61]. Expression of colipase, a critical 
protein factor for lipid metabolism, and subsequent stimulation of the release of 
pancreatic lipases appear to be regulated by Bacteroides thetaiotaomicron [59].
The metabolism of tryptophan by the HIM and/or gut and immune cells follows 
three alternative pathways: (a) the transformation to ligands of the aryl hydro-
carbon receptor (AhR), (b) the kynurenine pathway (via indoleamine 2,3-dioxy-
genase 1), and (c) the serotonin (5-HT) production pathway. These pathways 
are performed by HIM, enterocytes/immune cells, and enterochromaffin cells, 
respectively. The HIM pathway yields several molecules, indole-3-aldehyde, indole-
3-acid-acetic, indole-3-propionic acid, indole-3-acetaldehyde, and indoleacrylic 
acid. AhR signaling is crucial for gut epithelium renewal and barrier integrity and 
acts over many immune cell types for responsiveness [62].
Microbial metabolism of tryptophan is very important for intestinal AhR activ-
ity, since the absence or imbalance of tryptophan-metabolizing organisms generate 
deficiency of AhR agonists [46]. The production of AhR ligands have been deter-
mined among few HIM species, Peptostreptococcus russellii and Lactobacillus ssp. 
Many GI and neuropsychiatric diseases have been related to dysbiotic impairment 
of tryptophan metabolism or to accumulation of the end products [62].
Several HIM species not only can synthesize but respond as well to hormones and 
neurotransmitters of bacterial and human origin, which impact their growth and 
virulence. Beneficial Lactobacillus spp. are able to synthesize acetylcholine and gamma-
aminobutyric acid (GABA), while Bifidobacterium spp. produce GABA. Escherichia 
spp. produce norepinephrine, serotonin, and dopamine; other Firmicutes species 
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Pathway Metabolite Microbial agent Health benefits Refs.
Carbohydrate 
metabolism
Butyrate Clostridia (clusters 
IV and IVa)
Increased intestinal barrier function [30, 31]
Faecalibacterium. 
Prausnitzii
Modulate intestinal macrophage 
function
[32]
Eubacterium spp. Regulation of colonic regulatory T 
cell homeostasis
[33, 34]
Roseburia spp. Induction of tolerogenic dendritic 
cells that polarize naive CD4+ T cells 
toward IL-10–producing regulatory 
T cells
[35]
Coprococcus catus Suppression of colonic inflammation [36, 37]
Anaerostipes hadrus Improvements in insulin sensitivity [38]
Propionate Bacteroides spp. Regulation of colonic regulatory T 
cell homeostasis
[33, 34]
Blautia obeum Suppression of colonic inflammation [39]
C. catus Decreased innate immune responses 
to microbial stimulation
[40]
Roseburia 
inulinivorans
Protection from allergic airway 
inflammation
[41]
P. copri Improvements in insulin sensitivity 
and weight control in obese mice
[42]
Tryptophan 
metabolism
Indole Various 
tryptophanase-
producing bacteria 
such as
Lactobacillus spp.
Maintenance of host–microbe 
homeostasis at mucosal surfaces via 
IL-22
[43]
B. longum Increased barrier function [44]
B. fragilis Modulation of host metabolism [45]
I3A Lactobacillus spp. Maintenance of mucosal homeostasis 
and intestinal barrier function 
Protection against mouse intestinal 
inflammation.
[43, 46]
IPA Clostridium 
sporogenes
• Maintenance of intestinal barrier 
function and mucosal homeostasis
• Increased production of 
antioxidant and neuroprotectant 
molecules
[47, 48]
Llipid 
metabolism
HYA Lactobacillus spp. • Maintenance of intestinal barrier 
function
• Decreased inflammation
• Increased intestinal IgA 
production
[49, 50]
CLA Lactobacillus spp. Decreased inflammation [51]
Bifidobacterium 
spp.
Reduced adiposity [52]
F. prausnitzii Improved insulin sensitivity [53]
I3A, indole-3-aldehyde; IPA, indole-3-propionate; HYA, 10-hydroxy-cis-12-octadecoate (linoleic acid derivative); 
CLA, conjugated linoleic acid.
Modified from [29].
Table 1. 
Examples of intestinal microbiota-derived metabolites and their beneficial effects on human health.
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belonging to Streptococcus and Enterococcus produce serotonin, and Bacillus produce 
norepinephrine and dopamine [17]. Those bacteria-derived neurotransmitters released 
directly to the intestinal lumen may either induce epithelial cells to in turn release 
molecules that modulate neural signaling within the enteric nervous system (ENS) 
or, after passing through the gut wall, gain entry into the portal circulation to exert 
direct effects on afferent axons [63, 64]. Indeed, several reports documented elevated 
levels of noradrenaline and adrenaline in the plasma of subjects coursing with systemic 
infections by gram-negative Proteobacteria, like Escherichia coli. (Reviewed in [64]).
2.2 Stability of HIM
Bacterial colonization of the human gut likely occurs at the time of birth, when 
infants born via vaginal delivery are inoculated with a complex mixture of maternal 
vaginal microorganisms. According to Dominguez-Bello et al. [65], those infants 
had colonizing Lactobacillus, Prevotella, or Sneathia species in their skin and muco-
sae, which resembled their own mother’s vaginal microbiota. In contrast, infants 
delivered by cesarean section had predominantly Staphylococcus, Corynebacterium, 
and Propionibacterium species, akin to their mothers’ skin microbiota. Thus, there 
is concern that babies delivered via cesarean section may receive an insufficient 
maternal bacterial load [17].
After birth, breastfeeding is the main factor defining the composition of new-
born’s GI microbiota, since breast milk provides a variety of specific antibodies and 
immediate immunity molecules that neutralize pathogenic bacteria. Breast milk 
also contains more than 200 oligosaccharides (prebiotics) that favor the growth 
of bifidobacteria [66, 67], which have been reported to prevent gastrointestinal 
infections by competitive exclusion of pathogens based on common binding sites 
on epithelial cells [67]. Therefore, in breastfed children, bifidobacteria reaches 
up to 90% of GI microbiota, followed by lactobacilli, Bacteroides, coliforms, and 
clostridia. In contrast, infants fed with infant formula have predominance of 
Bacteroides, enterococci, coliforms, and clostridia, with much lesser bifidobacteria, 
resembling the more diverse GI microbiota of adults [66, 67].
The initial breastfeeding-driven colonization is essential for induction of 
adaptive immunity and for early metabolic programming. After the introduction 
of complementary feeding, the microbiota differences between breastfed children 
and those fed with formula tend to disappear. It is assumed that the predominant 
bacteria in the intestinal microbiome of 3-year-olds are similar to those of adults 
and remain relatively stable lifelong [66, 67].
Daily variability of the HIM composition has been assessed in controlled feed-
ing studies, specifically short-term administration of extreme amount of fat and 
fiber intake, which revealed disturbance of the intestinal microbiome, but this 
effect was of low-scale and transient that not changed the individual’s enterotype 
designation [66, 67].
3. Gut-to-brain axis
The basis of the GBA cross-communication includes an array of multichannel 
sensing and trafficking pathways (neural, endocrine, immune, and metabolic) to 
transfer the enteric signals to the brain (Figure 1), which ultimate results in keeping 
proper maintenance of GI homeostasis, although its multiple effects likely impacts 
on brain performance and higher cognitive functions [1–3, 68].
The GBA comprises highly interconnected body systems. Those systems are the 
CNS, the autonomic nervous system (vagal and spinal nerves), and the ENS  
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(the arrangement of neurons and supporting cells throughout and embedded 
within GI tract, from the esophagus to the anus). Other critical components of GBA 
include the hypothalamic pituitary adrenal axis (HPA; release of gut hormones), 
the immune system (release of multiple cytokines), and bacteria-derived metabo-
lites (SCFAs and free amino acids). In fact, gut microbes have evolved alongside 
their host, through complex relationships, so influencing their own genotypic and 
phenotypic features [1–3]. However, failures in the GBA cross talk may lead to a 
number of health disorders, from inflammatory to metabolic and neurodevelop-
mental conditions, including ASD [1].
The following pathways may explain the influence of the gut microbiota on 
neurologic disorders through GBA: (a) production of neurotransmitters, (b) triggering 
release of gut hormones from entero-endocrine cells, (c) stimulation of the ENS and 
signaling to the brain via ascending neural pathways, and (d) activation of the immune 
system via cytokine release by the mucosa-associated immune cells.
At physiological conditions, GBA modulates the digestive processes like motility 
and secretion, immune function, and perception and emotional response to visceral 
stimuli [17]. The high comorbidity of stress-related neurologic disorders with GI 
disorders proves the impact of altered function of GBA [3].
4. Autism spectrum disorders
ASD is a group of neurodevelopmental abnormalities whose clinical manifes-
tations begin in early childhood (although their diagnosis may delay months to 
years later in life). Clinically ASDs show complex and heterogeneous features but 
Figure 1. 
The bidirectional pathways of the gut-to-brain axis and their effects. Modulation of the CNS by the 
gut microbiome (through microbial-derived molecules such as SCFAs, neurotransmitters, hormones and 
tryptophan metabolites) occurs primarily via neuro-immune and neuroendocrine mechanisms. Those microbial 
molecules reach brain sites directly or only induce central responses through long-distance neural signaling 
by vagal and/or spinal afferents. The autonomic nervous system regulates gut functions (motility, secretion, 
intestinal permeability, and mucosal immune response), which ultimately affect the microbial habitat, thereby 
modulating microbiota composition and activity.
Microorganisms
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generally are defined by a core symptomatology including impaired social commu-
nication (oral and nonverbal languages, eye contact), behavioral problems (fixated 
interests in the daily routine, engagement in repetitive manners, exacerbated 
responses to external stimuli), and self-isolation, with or without impairment of 
cognitive abilities and competences [9, 69].
According to the latest American Psychiatric Association’s diagnostic criteria 
[69], ASDs include conditions known as autism disorder (AD), Asperger’s syn-
drome, childhood disintegrative disorder, and pervasive developmental disorder 
not otherwise specified (PDD-NOS).
Noteworthy ASD clinical features show extensive heterogeneity among affected 
subjects, according to the developmental stage, to chronological age, and to specific 
disorder within the spectrum (and even within the same disorder) [9, 69].
Until of April 2018, ASD were estimated to affect, in average, 1 in every 160 
children worldwide, with a yearly rising incidence, and an estimated boy to girl 
ratio of 5:1 [70]. Data from the USA reveal that prevalence of ASDs has dramatically 
increased from 4.5 in 10,000 children in 1966 to 1 in 68 in 2010 and finally to 1 in 59 
children in 2014 [71].
This recent outburst in frequency may be partly attributed to increased public 
awareness and or to better diagnosis; however, the occurrence of other factors, such 
as exposure to environmental chemicals, diet alterations, metabolic status, and 
changes in microbiota composition, cannot be excluded [17].
Despite the alarming rise trend in frequency of diagnosed cases in developed 
countries, the etiopathogenesis of ASD is still unknown; thus, there are no consen-
sus in medical, neurologic, or psychiatric treatments [10]. Moreover, a diversity of 
comorbidities also affect ASD individuals, including one or more of the following: 
anxiety, intellectual disability, epilepsy/seizures, attention deficit and hyperactivity 
disorder, GI disorders, sleep disorders, obesity, depression, bipolar disorder, and 
Tourette’s syndrome, among others (Figure 2) [6, 7, 9].
Among the most frequent GI comorbidities in ASD subjects are exacerbated flatu-
lence (60%), bloating (38%), abdominal pain (37%), diarrhea (28%), burping/belch-
ing (25%), gastroesophageal reflux symptoms (16%), and constipation (10%) [8].
Figure 2. 
Relevant features of ASD and their most frequent comorbidities. The colored figures represent typical features 
defining ASD, while colorless figures represent the most prevalent of its comorbidities. ADHD, attention deficit 
and hyperactivity disorder; GI, gastrointestinal, OCD, obsesive –compulsive disorder.
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Research on ASD was primarily focused on genetic associations, but recent evi-
dence has suggested that other environmental factors, including pre- or postnatal 
exposure to chemicals and drugs, air pollution, stress, maternal infection, the HIM, 
and dietary factors, may play a role in the clinical manifestations of the ASD [17].
5. Interplay between HIM and GBA in the context of ASD
About 40–60% of ASD children suffer from gastrointestinal comorbidities [8], 
although due to their social and communicative impairments, the real prevalence of 
gastrointestinal issues among ASD patients may be higher. Such intestinal dysfunc-
tion in this group of patients may be caused by disturbances in the pathways under-
lying the GBA, with a central role of the HIM and including an immune component.
Several studies have demonstrated HIM dysbiosis in ASD subjects; however, 
little or null correlation between studies has been obtained, mainly due to variations 
in study groups, control groups, and the use of diverse methods for microbiota/
microbiome determinations and analysis (Table 2) [67, 72]. In short, 13 of the 15 
studies showed some degree of dysbiosis among ASD patients as compared with 
controls (total combined sample of 585 individuals, 339 ASD, 61 control siblings, 
and 185 unrelated neurotypical controls), whereas 2 of the 15 studies found no 
significant differences among ASD subjects as compared with siblings controls (no 
neurotypical controls were included).
Altogether the microbiome data from the studies showed in Table 2 suggests 
some important features among stool samples of ASD subjects: (a) levels of clos-
tridia, Desulfovibrio, and Sutterella seem consistently elevated; (b) on the opposite, 
levels of Prevotella and bifidobacteria appears to be reduced; (c) the Bacteroidetes/
Firmicutes ratio showed inconsistent results over different cohorts. There are sig-
nificant, but not consistent, distinctive different microbiome compositions in ASD 
patients, regardless of gastrointestinal problems, compared to controls [73–90]. 
Moreover, the presence of HIM dysbiosis may correlate with ASD phenotype [91].
Dysbiosis in ASD is also associated with increased permeability of the GI tract, 
the leaky gut, which leads to the entry of endotoxins, and other bacterial products 
into the bloodstream [92]. Bacterial lipopolysaccharide (LPS) can alter neuronal as 
well as microglial activity in brain regions involved in emotional control [93–95]. In 
fact, serum levels of LPS were significantly higher among ASD subjects compared 
to healthy individuals and correlated with impaired social behavioral scores [96].
Serotonin synthesis in the gut and the brain depends on the availability of 
dietary tryptophan. High levels of blood serotonin were found in children with ASD 
[97–99], which contrasts with finding of decreased brain serotonin synthesis in 
ASD subjects [100]. A significant correlation between whole-blood serotonin levels 
and low-grade intestinal inflammation in ASD was demonstrated [101]. Regarding 
these findings, a likely explanation was proposed by de Theije et al. (2011) [91]: 
After GI inflammation, the intestinal serotonin release provokes changes in motil-
ity, secretion, vasodilation, and permeability, leading to functional intestinal 
dysmotility, stool inconsistency, and abdominal pain. Since the majority of dietary 
tryptophan is transformed in serotonin by HIM during inflammation, less trypto-
phan (and serotonin) will be available for the brain resulting in mood and cognitive 
dysfunction in ASD and increased autistic behavior [102].
Propionic acid, a major SCFA produced by clostridia, Bacteroides, and 
Desulfovibrio, has been associated with ASD, since it can induce ASD-like behavioral 
deficits in rats [103, 104]. Detrimental effects of propionic acid are suggested to be 
through mitochondrial and epigenetic modulation of ASD-associated genes. In fact, 
elevated levels of SCFAs are described in the stool of ASD children [82, 105].
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Country (Year) Study Group Specimen 
type
Analytical 
method
Changes in fecal microbiome in ASD Refs.
ASD (GI+/GI−) SIB (GI+/GI−) NTC (GI+GI−)
USA (2002) 13 – 8 Stool Bacterial 
cultures
↑ Nine species of Clostridium [73]
USA (2004) 15 – 8 Stool 16S rRNA gene 
sequencing
↑ C. bolteae and cluster I/IX [74]
United Kingdom 
(2005)
58 12 10 Stool FISH analysis ↑ C. histolyticum and cluster I/II.
Siblings show intermediate levels.
[75]
USA (2010) 33 (33/0) 7 (0/7) 8 (0/8) Stool 16S rRNA gene 
sequencing
↑ Bacteroidetes and Proteobacteria: Desulfovibrio, 
B. Alkaliflexus, Acetanaerobacterium, Parabacteroides
↓ Firmicutes and Actinobacteria: Clostridium, Weissella, 
Turicibacter, Anaerofilum, Ruminococcus, Streptococcus, 
Pseudoramibacter,
[76]
USA (2011) 58 (58/0) – 39 (0/39) Stool Bacterial 
cultures
↓ Bifidobacterium and Enterococcus
↑ Bacillus spp. (Lactobacillus)
[77]
Poland (2011) 41 – 10 Stool Bacterial
cultures
↑ Clostridium perfringens [78]
USA (2011, 
2012)
23 (23/0) – 9 (9/0) Intestinal 
biopsies
16S rRNA gene 
sequencing
↓ Bacteroidetes
↑ Firmicutes, Proteobacteria, Sutterella
[79, 80]
Australia (2011, 
2012 2013)
23 (9/14) 22 (6/16) 9 (1/8) Stool Targeted qPCR
GC
HPLC
↓Bifidobacterium spp., Akkermansia muciniphilia
↑ Sutterella spp.
(↑ Relative abundance of Clostridium difficile in ASD, NS)
↑ Ruminococcus torques (only in ASD-GI+).
↑Ammonia and SCFA (acetic, butyric, isobutyric, valeric, 
isovaleric acids), likely microbial-derived.
No differences in phenol and p-cresol levels
[81–83]
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Country (Year) Study Group Specimen 
type
Analytical 
method
Changes in fecal microbiome in ASD Refs.
ASD (GI+/GI−) SIB (GI+/GI−) NTC (GI+GI−)
Australia (2012) 51 (28/23) 53 (4/49) – Stool 16S rRNA gene 
sequencing
No differences [84]
USA (2013) 20 (20/0) – 20 (0/20) Stool 16S rRNA gene 
sequencing
↓ Prevotella, Coprocuccus, Veillonellaceae [85]
Italy (2013) 10 10 10 Stool 16S rRNA gene 
sequencing 
GC-MS/SPME
↓ Caloramator, Sarcina, Clostridium, Sutterellaceae
↓ Eubacterium, Bifidobacterium
↓SCFA (except PPA)
↑ Phenol, 4-(1,1-dimethylethyl)-phenol, and p-cresol.
↑ Free amino acids (Proteolytic bacteria)
[86]
USA (2015) 59 (25/34) 44 (13/31) - Stool 16S rRNA gene 
sequencing
No differences [87]
Slovakia (2015) 10 10 10 Stool Targeted qPCR ↓Bacteroidetes/Firmicutes
↑ Lactobacillus spp.
(↑Clostridia cluster I and Desulfovibrio, NS.)
Desulfovibrio spp.: strong positive association with ASD 
severity
[88]
USA (2017) 14 (14/0) - 21 (15/6) Rectal 
biopsies
16S rDNA PCR 
and sequencing
HPLC of 
mucosal 
supernatant.
↑ Clostridiales (C lituseburense, Lachnoclostridum bolteae, L 
hathewayi, C aldenense, and Flavonifractor plautii)
↓ Dorea formicigenerans, Blautia luti, Sutterella spp.
↓Tryptophan (correlation with ↑Erysipelotrichaceae, C. 
lituseburense, and Terrisporobacter )
↑ Serotonergic metabolites, including 5-HIAA (associated 
with abdominal pain and with the following:
↓ Akkermansia muciniphila, Coprococcus catus, Odoribacter 
splanchnicus, C. lactatifermentans, and Ruminococcus 
lactaris;
↑ L. bolteae, L. hathewayi, and F. plautii).
[89]
M
icroorgan
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s
12
Country (Year) Study Group Specimen 
type
Analytical 
method
Changes in fecal microbiome in ASD Refs.
ASD (GI+/GI−) SIB (GI+/GI−) NTC (GI+GI−)
USA (2018) 21 - 23 Stool 1H NMR 
spectroscopy
16S rRNA gene 
sequencing
↑ Isopropanol, p-cresol.
↓ GABA (associated to ↓ Streptococcus thermophiles)
↓Phylotypes closely related to Prevotella copri ,
↓ Feacalibacterium prausnitzii and Haemophilus 
parainfluenzae.
[90]
Data presented here include microbial phylotypes or species and/or relevant metabolites pertaining ASD-associated alterations, compared to non-ASD siblings or unrelated healthy controls.
ASD, children with autism spectrum disorder; SIB, siblings without ASD; NTC, neuro typical controls; GI+, with gastrointestinal comorbidities; GI−, without gastrointestinal comorbidities, ↑, increased 
level(s); ↓, decreased level(s); NS, non statistically significant; FISH, fluorescent in situ hybridization; GC, gas chromatography; HPLC, high performance liquid chromtography; SCFA, short-chain fatty 
acids; PPA, propionic acid MS, mass spectroscopy; SPME, solid phase microextraction; 5-HIAA: 5-hydoxy-indoleacetic acid; H-NMR, proton nuclear magnetic resonance; GABA, gamma-amino butyric acid.
Table 2. 
Studies on gut microbiome in ASD.
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Scientific literature supports the notion that the HIM plays a crucial role in the 
pathogenesis of ASD, so scientists are now targeting gut microbiome as a thera-
peutic approach for such disorder (reviewed in [106]). First, modification of high 
lipid and sugar diet for a fiber- and protein-containing one showed improved skills 
while ameliorated ASD behavioral deficits. Second, supplementation with prebiot-
ics (inulin, fructo-oligosaccharides, galacto-oligosaccharides, and lactulose) allows 
specific changes, both in the composition and/or activity of the gut microflora, 
mainly inducing the growth of indigenous lactobacilli and bifidobacteria. Third, 
probiotics administration, either Bacteroides fragilis or Lactobacillus reuteri, there 
were improvements in ASD-associated behaviors, counteract effect of harmful 
infections and stimulation of the host’s immune system. Fourth, fecal microbiota 
transplant, usually applied for treating recurrent Clostridium difficile infection 
and other GI disorders, consists of a sample containing about a thousand indig-
enous bacterial species of the GI from a neurotypical donor, treatment showed 
sustained improvement of both GI- and ASD related symptoms (up to 8 weeks 
posttreatment).
6. Conclusion
After the complete sequencing of the human genome was achieved, the scien-
tific community began, in the second half of the past decade, the task of mapping 
the human microbiota, mainly the intestinal microbiota. In parallel, the notion that 
the ENS interplay with the intestinal microbiota, generating responses in the CNS, 
through the GBA and HPA axis, has opened an avenue for the study of gastrointesti-
nal, metabolic, and/or neuropsychiatric disorders.
In this landscape, an increasing body of evidence suggests that HIM has a key 
role in gut and brain development and functionality but also in pathogenesis of 
mental disorders, including ASD. Studies on ASD have showed that HIM dysbiosis, 
with altered Bacteroidetes/Firmicutes ratio, presence of detrimental key species, 
and dysregulation of bacterial metabolite release, appears to correlate with severity 
of ASD symptoms. In this regard, intervention measures to restore HIM homeosta-
sis are likely promising.
However, the part concerning the microbiota is only one more piece of the 
puzzle that are ASDs, mainly because the etiology of such disorders remains elusive.
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